Elamipretide (SS-31)
SS-31 / MTP-131 / Forzinity
- Peptide length
- 4 amino acids
Modified tetrapeptide
Open the sources to check how the studies were done and what they can support.
A mitochondria-targeted peptide. FDA granted Forzinity accelerated approval in 2025 to improve muscle strength in patients with Barth syndrome weighing at least 30 kg.
- Family
- Mitochondria-targeted peptide
- Research target
- Cardiolipin-associated mitochondrial membrane
- Molecular form
- Modified tetrapeptide
What to know about the research
Accelerated approval used an intermediate clinical endpoint and requires confirmation of benefit. It does not establish broad anti-aging or exercise benefits.
Check the exact compound
Distinguish the regulated elamipretide product from research preparations labeled SS-31 and preserve its modified-residue stereochemistry.
What supports this entry?
The reference list is available. A statement-by-statement source check has not been completed for this entry.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
No study details have been extracted for this exact entry yet. This does not mean that no studies exist. Open the references and check the exact material.
How we prepare and correct these entries